Flu Speed Ahead in Vaccines Market

Large investments by GlaxoSmithKline and Novartis in the US flu vaccine business highlight a rush back into the business. Government subsidies, technical assistance and market creation are making the flu vaccine field an attractive section of the pharma field again. It has been generally viewed for decades as a risky, difficult buisness with very little growth potential. Now the tables have turned.